GeneDx (NASDAQ:WGS) Receives “Buy” Rating from BTIG Research

GeneDx (NASDAQ:WGS)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $90.00 price target on the stock. BTIG Research’s target price would suggest a potential upside of 32.63% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $63.00 price target (up from $50.00) on shares of GeneDx in a research note on Tuesday, June 23rd. TD Cowen reissued a “buy” rating on shares of GeneDx in a research note on Wednesday, July 15th. Weiss Ratings cut shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Craig Hallum restated a “buy” rating and issued a $85.00 target price on shares of GeneDx in a report on Tuesday, May 5th. Finally, Canaccord Genuity Group set a $75.00 target price on GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and an average target price of $87.43.

GeneDx Trading Up 4.2%

NASDAQ WGS opened at $67.86 on Tuesday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx has a 1-year low of $32.21 and a 1-year high of $170.87. The firm’s fifty day simple moving average is $61.08 and its 200-day simple moving average is $69.30. The company has a market capitalization of $2.01 billion, a PE ratio of -25.32 and a beta of 1.92.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.20. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $114.44 million during the quarter, compared to analysts’ expectations of $111.01 million. During the same quarter last year, the firm earned $0.36 earnings per share. As a group, sell-side analysts anticipate that GeneDx will post -1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GeneDx news, Director Keith A. Meister acquired 46,273 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $38.91 per share, for a total transaction of $1,800,482.43. Following the completion of the purchase, the director owned 4,784,570 shares of the company’s stock, valued at approximately $186,167,618.70. This trade represents a 0.98% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Casdin Capital, Llc acquired 50,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $52.86 per share, with a total value of $2,643,000.00. Following the transaction, the director directly owned 3,707,164 shares in the company, valued at $195,960,689.04. The trade was a 1.37% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. 25.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Westfield Capital Management Co. LP increased its position in shares of GeneDx by 87.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after purchasing an additional 474,167 shares in the last quarter. Franklin Resources Inc. boosted its position in GeneDx by 60.4% in the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock valued at $142,154,000 after buying an additional 411,607 shares in the last quarter. Invesco Ltd. boosted its position in GeneDx by 59.2% in the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock valued at $102,288,000 after buying an additional 292,394 shares in the last quarter. Amova Asset Management Americas Inc. grew its stake in GeneDx by 67.3% during the first quarter. Amova Asset Management Americas Inc. now owns 638,800 shares of the company’s stock worth $41,024,000 after buying an additional 257,075 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in GeneDx by 65.9% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 633,457 shares of the company’s stock worth $40,681,000 after buying an additional 251,732 shares during the last quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Quarterly results beat estimates: GeneDx reported adjusted EPS of $0.01, above the consensus estimate of a $0.19 loss, while revenue increased 11.4% year over year to $114.4 million, ahead of expectations. GeneDx quarterly earnings report
• Positive Sentiment: Full-year revenue guidance reaffirmed: Management maintained its 2026 revenue forecast of $475 million to $490 million, broadly in line with the $477.1 million analyst consensus. The company expects a meaningful improvement in collection rates beginning in the fourth quarter, which could support future revenue quality and cash generation. GeneDx reaffirms 2026 revenue guidance
• Positive Sentiment: Gross profit increased: Gross profit rose approximately 10% to $78.2 million, indicating that GeneDx continues to expand its top line despite a challenging profitability environment. GeneDx second-quarter financial results
• Neutral Sentiment: Investor positioning is mixed: Recent institutional filings showed both sizable additions and reductions in WGS positions. Reported insider activity was also mixed, with large purchases by certain investors alongside sales by company executives, offering no clear signal about near-term sentiment.
• Negative Sentiment: Profitability and cash flow remain weak: GeneDx posted a $17.5 million operating loss, a $17.7 million net loss, and $29 million in operating cash outflow. Losses worsened from the prior year, while cash stood at $60.3 million and total liabilities reached $237.3 million. GeneDx Q2 losses and cash flow report
• Negative Sentiment: Securities litigation adds risk: Several law firms publicized a class-action lawsuit alleging securities-law violations related to purchases made between April 16, 2025, and May 4, 2026. The allegations are not proven, but the litigation could create financial, reputational, and management risks. GeneDx securities class action announcement

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.